February 6, 2019 / 11:35 AM / 12 days ago

Eli Lilly quarterly sales beat expectations

Feb 6 (Reuters) - Eli Lilly and Co posted better-than-expected fourth-quarter revenue on Wednesday, helped by higher sales of its newer drugs such as diabetes treatment Trulicity and psoriatic arthritis medication Taltz.

Revenue rose 4.5 percent to $6.44 billion, beating the average analyst estimate of $6.29 billion, according to IBES data from Refinitiv.

The company posted net income of $1.13 billion, or $1.10 per share, in the fourth quarter ended Dec. 31, compared with a net loss of $1.66 billion, or $1.58 per share, a year earlier, when it recorded charges related to the U.S. tax overhaul.

Reporting by Manogna Maddipatla in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below